271 related articles for article (PubMed ID: 31795400)
1. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
Battah B; Chemi G; Butini S; Campiani G; Brogi S; Delogu G; Gemma S
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795400
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
[TBL] [Abstract][Full Text] [Related]
4. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach.
Madugula SS; Nagamani S; Jamir E; Priyadarsinee L; Sastry GN
Mol Divers; 2022 Jun; 26(3):1675-1695. PubMed ID: 34468898
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis.
Brindha S; Vincent S; Velmurugan D; Ananthakrishnan D; Sundaramurthi JC; Gnanadoss JJ
Med Hypotheses; 2017 Jun; 103():39-45. PubMed ID: 28571806
[TBL] [Abstract][Full Text] [Related]
6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
7. Bis-biguanide dihydrochloride inhibits intracellular replication of M. tuberculosis and controls infection in mice.
Shen H; Wang F; Zeng G; Shen L; Cheng H; Huang D; Wang R; Rong L; Chen ZW
Sci Rep; 2016 Sep; 6():32725. PubMed ID: 27601302
[TBL] [Abstract][Full Text] [Related]
8. Polypharmacological repurposing approach identifies approved drugs as potential inhibitors of Mycobacterium tuberculosis.
Singh J; Quadir N; Vashishtha S; Chakraborty A; Alam A; Kundu B; Ahmad U; Sundar D; Ehtesham NZ; Hasnain SE
Biochem J; 2023 Jul; 480(14):1079-1096. PubMed ID: 37306466
[TBL] [Abstract][Full Text] [Related]
9. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
10. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
11. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted role of drugs: a potential weapon to outsmart
Tanweer S; Jamal S; Mehra S; Saqib N; Ahmad F; Faizan ; Grover A; Grover S
J Biomol Struct Dyn; 2022 Nov; 40(18):8508-8517. PubMed ID: 33860725
[TBL] [Abstract][Full Text] [Related]
13. Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.
Ramakrishnan G; Chandra NR; Srinivasan N
Mol Biosyst; 2015 Dec; 11(12):3316-31. PubMed ID: 26429199
[TBL] [Abstract][Full Text] [Related]
14. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
16. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
[TBL] [Abstract][Full Text] [Related]
17. In silico Screening of Food and Drug Administration-approved Compounds against Trehalose 2-sulfotransferase (Rv0295c) in Mycobacterium tuberculosis: Insights from Molecular Docking and Dynamics Simulations.
Sharma D; Gautam S; Srivastava N; Bisht D
Int J Mycobacteriol; 2024 Jan; 13(1):73-82. PubMed ID: 38771283
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of FDA-approved drugs to target MurB and MurE enzymes in
Rani J; Silla Y; Borah K; Ramachandran S; Bajpai U
J Biomol Struct Dyn; 2020 Jun; 38(9):2521-2532. PubMed ID: 31244382
[TBL] [Abstract][Full Text] [Related]
19. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
[TBL] [Abstract][Full Text] [Related]
20. Computational, crystallographic studies, cytotoxicity and anti-tubercular activity of substituted 7-methoxy-indolizine analogues.
Venugopala KN; Chandrashekharappa S; Pillay M; Abdallah HH; Mahomoodally FM; Bhandary S; Chopra D; Attimarad M; Aldhubiab BE; Nair AB; Sreeharsha N; Morsy MA; Pottathil S; Venugopala R; Odhav B; Mlisana K
PLoS One; 2019; 14(6):e0217270. PubMed ID: 31163040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
